Physician profile
Timothy Gammons
NPI 1730163023
$9,357.47
in general payments reported to CMS, 2019-2025
24 companies · $238 in 2025
The $238 reported for 2025 was more than what a typical Addiction Medicine (Family Medicine) provider received nationally (typical 2025 total: $143).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,882 · 2020: $352 · 2021: $324 · 2022: $1,060 · 2023: $199 · 2024: $303 · 2025: $238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $739.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $739.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orexo US, INC. | $3,591.83 | 2019-2025 | Zubsolv |
| Sandoz INC. | $3,285.00 | 2019 | |
| Indivior INC. | $840.93 | 2019-2024 | Sublocade |
| Abbvie INC. | $464.50 | 2021-2025 | |
| Allergan, INC. | $294.79 | 2019-2020 | |
| Pfizer INC. | $185.51 | 2019-2024 | |
| Gilead Sciences, INC. | $141.86 | 2019-2025 | |
| Exact Sciences Corporation | $85.03 | 2025 | Cologuard Collection Kit |
| Uswm, LLC | $70.28 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $67.04 | 2022-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $55.10 | 2024 | Austedo Xr |
| Alkermes, INC. | $43.43 | 2019-2020 | |
| Braeburn INC. | $33.47 | 2024-2025 | Brixadi |
| Biohaven Pharmaceuticals, INC. | $31.63 | 2021 | |
| Hologic Sales and Service, LLC | $22.14 | 2023 | Aptima |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $18.86 | 2023 | Breztri |
| Lilly USA, LLC | $18.79 | 2020 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $18.72 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $17.77 | 2025 | Uptravi, Opsumit |
| Takeda Pharmaceuticals U.S.A., INC. | $17.21 | 2022 | |
| Biodelivery Sciences International, INC. | $14.22 | 2019 | |
| Horizon Therapeutics Plc | $13.62 | 2019 | |
| Mdd US Operations, LLC | $13.43 | 2019 | |
| Titan Pharmaceuticals, INC. | $12.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Gammons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.